IBDEI114 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16546,1,4,0)
 ;;=4^C34.90
 ;;^UTILITY(U,$J,358.3,16546,2)
 ;;=^5000966
 ;;^UTILITY(U,$J,358.3,16547,0)
 ;;=C65.9^^88^879^154
 ;;^UTILITY(U,$J,358.3,16547,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16547,1,3,0)
 ;;=3^Malig Neop Renal Pelvis,Unspec
 ;;^UTILITY(U,$J,358.3,16547,1,4,0)
 ;;=4^C65.9
 ;;^UTILITY(U,$J,358.3,16547,2)
 ;;=^5001253
 ;;^UTILITY(U,$J,358.3,16548,0)
 ;;=C50.912^^88^879^135
 ;;^UTILITY(U,$J,358.3,16548,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16548,1,3,0)
 ;;=3^Malig Neop Left Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,16548,1,4,0)
 ;;=4^C50.912
 ;;^UTILITY(U,$J,358.3,16548,2)
 ;;=^5001196
 ;;^UTILITY(U,$J,358.3,16549,0)
 ;;=C50.911^^88^879^157
 ;;^UTILITY(U,$J,358.3,16549,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16549,1,3,0)
 ;;=3^Malig Neop Right Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,16549,1,4,0)
 ;;=4^C50.911
 ;;^UTILITY(U,$J,358.3,16549,2)
 ;;=^5001195
 ;;^UTILITY(U,$J,358.3,16550,0)
 ;;=C50.919^^88^879^127
 ;;^UTILITY(U,$J,358.3,16550,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16550,1,3,0)
 ;;=3^Malig Neop Female Breast,Unspec Site
 ;;^UTILITY(U,$J,358.3,16550,1,4,0)
 ;;=4^C50.919
 ;;^UTILITY(U,$J,358.3,16550,2)
 ;;=^5001197
 ;;^UTILITY(U,$J,358.3,16551,0)
 ;;=C62.90^^88^879^165
 ;;^UTILITY(U,$J,358.3,16551,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16551,1,3,0)
 ;;=3^Malig Neop Testis,Unspec
 ;;^UTILITY(U,$J,358.3,16551,1,4,0)
 ;;=4^C62.90
 ;;^UTILITY(U,$J,358.3,16551,2)
 ;;=^5001236
 ;;^UTILITY(U,$J,358.3,16552,0)
 ;;=D03.9^^88^879^170
 ;;^UTILITY(U,$J,358.3,16552,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16552,1,3,0)
 ;;=3^Melanoma in Situ,Unspec
 ;;^UTILITY(U,$J,358.3,16552,1,4,0)
 ;;=4^D03.9
 ;;^UTILITY(U,$J,358.3,16552,2)
 ;;=^5001908
 ;;^UTILITY(U,$J,358.3,16553,0)
 ;;=C45.0^^88^879^171
 ;;^UTILITY(U,$J,358.3,16553,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16553,1,3,0)
 ;;=3^Mesothelioma of Pleura
 ;;^UTILITY(U,$J,358.3,16553,1,4,0)
 ;;=4^C45.0
 ;;^UTILITY(U,$J,358.3,16553,2)
 ;;=^5001095
 ;;^UTILITY(U,$J,358.3,16554,0)
 ;;=C90.01^^88^879^173
 ;;^UTILITY(U,$J,358.3,16554,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16554,1,3,0)
 ;;=3^Multiple Myeloma,In Remission
 ;;^UTILITY(U,$J,358.3,16554,1,4,0)
 ;;=4^C90.01
 ;;^UTILITY(U,$J,358.3,16554,2)
 ;;=^267515
 ;;^UTILITY(U,$J,358.3,16555,0)
 ;;=C90.00^^88^879^174
 ;;^UTILITY(U,$J,358.3,16555,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16555,1,3,0)
 ;;=3^Multiple Myeloma,Not in Remission
 ;;^UTILITY(U,$J,358.3,16555,1,4,0)
 ;;=4^C90.00
 ;;^UTILITY(U,$J,358.3,16555,2)
 ;;=^5001752
 ;;^UTILITY(U,$J,358.3,16556,0)
 ;;=C94.6^^88^879^175
 ;;^UTILITY(U,$J,358.3,16556,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16556,1,3,0)
 ;;=3^Myelodysplastic Disease NEC
 ;;^UTILITY(U,$J,358.3,16556,1,4,0)
 ;;=4^C94.6
 ;;^UTILITY(U,$J,358.3,16556,2)
 ;;=^5001846
 ;;^UTILITY(U,$J,358.3,16557,0)
 ;;=D61.82^^88^879^176
 ;;^UTILITY(U,$J,358.3,16557,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16557,1,3,0)
 ;;=3^Myelophthisis
 ;;^UTILITY(U,$J,358.3,16557,1,4,0)
 ;;=4^D61.82
 ;;^UTILITY(U,$J,358.3,16557,2)
 ;;=^334037
 ;;^UTILITY(U,$J,358.3,16558,0)
 ;;=D47.9^^88^879^177
 ;;^UTILITY(U,$J,358.3,16558,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16558,1,3,0)
 ;;=3^Neop Lymphoid,Hematopoietic & Related Tissue,Uncertain Behavior
 ;;^UTILITY(U,$J,358.3,16558,1,4,0)
 ;;=4^D47.9
 ;;^UTILITY(U,$J,358.3,16558,2)
 ;;=^5002260
